drugset / Trial / NCT04489940
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
Phase 2
Terminated
11 enrolled
EMD Serono Research & Development Institute, Inc.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study was to evaluate bintrafusp alfa monotherapy in participants with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a centralized reverse transcriptase-polymerase chain reaction (RT-PCR) test.
Timeline
- Start
- 2020-10-12
- Primary completion
- 2022-01-27
- Completion
- 2022-07-08
Outcome
Outcome not reported
Stopped (Enrollment): “The study was prematurely discontinued by the sponsor due to probability of success which was too low to justify the continuation of recruitment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bintrafusp alfa | Protein / enzyme biologic | 1200 mg | Intravenous |